Publication date: Feb 13, 2020
While it is no crystal ball, a new blood test developed at Newcastle University and Cambridge University in the UK is offering hope of better patient management, with an ability to recognize early indicators of cognitive decline, dementia and progression of motor symptoms.
The study involved almost 250 subjects, of which more than 150 were patients recently diagnosed with Parkinson’s disease (PD).
The idea was to draw blood samples from the Parkinson’s patients and measure certain biomarkers to see how reliably they could serve as predictors of cognitive and motor decline over the following three years.
The team also identified other senescence and inflammatory biomarkers at the start of the study that proved to be indicators of accelerated motor and cognitive decline across the three-year period.
- Simple blood test could help predict progression of Parkinson’s disease
- Blood test for inflammatory and cell senescence biomarkers may help predict cognitive decline
- Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms.